Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningBone Marrow CellsBone Marrow TransplantationBone MarrowStem CellsTransplantation ChimeraHematologic NeoplasmsTissue DonorsTransplantation, AutologousHematopoietic Stem CellsPeripheral Blood Stem Cell TransplantationGraft SurvivalTreatment OutcomeHistocompatibility TestingWhole-Body IrradiationBusulfanGraft vs Leukemia EffectSiblingsRecurrenceMyeloablative AgonistsRemission InductionVidarabineLeukemiaImmunosuppressive AgentsCytomegalovirus InfectionsMultiple MyelomaGraft vs Tumor EffectLeukemia, Myeloid, AcuteRetrospective StudiesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHistocompatibilityCombined Modality TherapyLymphocyte TransfusionTime FactorsCord Blood Stem Cell TransplantationCell DifferentiationBone and BonesMyelodysplastic SyndromesEmbryonic Stem CellsMesenchymal Stem Cell TransplantationLymphocyte DepletionSurvival AnalysisSalvage TherapyHematopoietic Stem Cell MobilizationPrecursor Cell Lymphoblastic Leukemia-LymphomaAntigens, CD34Survival RateAdult Stem CellsDisease-Free SurvivalAnemia, AplasticImmunocompromised HostVirus ActivationKidney TransplantationMinor Histocompatibility AntigensAntilymphocyte SerumCytomegalovirusChimerismT-LymphocytesHepatic Veno-Occlusive DiseaseMelphalanHematopoiesisCyclophosphamideNeoplasm, ResidualCells, CulturedTransplantationLiver TransplantationHematologic DiseasesAcute DiseaseAntineoplastic Combined Chemotherapy ProtocolsFlow CytometryMice, Inbred C57BLCell TransplantationRoseolovirus InfectionsFollow-Up StudiesOpportunistic InfectionsPluripotent Stem CellsLeukemia, MyeloidImmunosuppressionGranulocyte Colony-Stimulating FactorGraft RejectionHLA AntigensColony-Forming Units AssayLiving DonorsStem Cell NichePrognosisTransplantation ImmunologyMesenchymal Stromal CellsPrimary MyelofibrosisLymphoproliferative DisordersAntineoplastic AgentsMycosesFatal OutcomeNeural Stem CellsStem Cell FactorBlood DonorsGanciclovir